Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia.

Lanza K, Meadows SM, Chambers NE, Nuss E, Deak MM, Ferré S, Bishop C.

Neuropharmacology. 2018 Aug;138:304-314. doi: 10.1016/j.neuropharm.2018.06.024. Epub 2018 Jun 21.

PMID:
29936243
2.

Consumer Sleep Technology: An American Academy of Sleep Medicine Position Statement.

Khosla S, Deak MC, Gault D, Goldstein CA, Hwang D, Kwon Y, O'Hearn D, Schutte-Rodin S, Yurcheshen M, Rosen IM, Kirsch DB, Chervin RD, Carden KA, Ramar K, Aurora RN, Kristo DA, Malhotra RK, Martin JL, Olson EJ, Rosen CL, Rowley JA; American Academy of Sleep Medicine Board of Directors.

J Clin Sleep Med. 2018 May 15;14(5):877-880. doi: 10.5664/jcsm.7128.

3.

Circulating Levels of Brain-Derived Neurotrophic Factor and History of Suicide Attempts in Women.

Kudinova AY, Deak T, Deak MM, Gibb BE.

Suicide Life Threat Behav. 2017 Sep 28. doi: 10.1111/sltb.12403. [Epub ahead of print]

PMID:
28960421
4.

Standardized LC×LC-ELSD Fractionation Procedure for the Identification of Minor Bioactives via the Enzymatic Screening of Natural Extracts.

Coulerie P, Ratinaud Y, Moco S, Merminod L, Naranjo Pinta M, Boccard J, Bultot L, Deak M, Sakamoto K, Queiroz EF, Wolfender JL, Barron D.

J Nat Prod. 2016 Nov 23;79(11):2856-2864. Epub 2016 Oct 28.

PMID:
27792327
5.

Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle.

Bultot L, Jensen TE, Lai YC, Madsen AL, Collodet C, Kviklyte S, Deak M, Yavari A, Foretz M, Ghaffari S, Bellahcene M, Ashrafian H, Rider MH, Richter EA, Sakamoto K.

Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E706-E719. doi: 10.1152/ajpendo.00237.2016. Epub 2016 Aug 30.

6.

Cyclin Y phosphorylation- and 14-3-3-binding-dependent activation of PCTAIRE-1/CDK16.

Shehata SN, Deak M, Morrice NA, Ohta E, Hunter RW, Kalscheuer VM, Sakamoto K.

Biochem J. 2015 Aug 1;469(3):409-20. doi: 10.1042/BJ20150486. Epub 2015 Jun 11.

7.

Motif affinity and mass spectrometry proteomic approach for the discovery of cellular AMPK targets: identification of mitochondrial fission factor as a new AMPK substrate.

Ducommun S, Deak M, Sumpton D, Ford RJ, Núñez Galindo A, Kussmann M, Viollet B, Steinberg GR, Foretz M, Dayon L, Morrice NA, Sakamoto K.

Cell Signal. 2015 May;27(5):978-88. doi: 10.1016/j.cellsig.2015.02.008. Epub 2015 Feb 13.

8.

Novel role for galectin-1 in T-cells under physiological and pathological conditions.

Deák M, Hornung Á, Novák J, Demydenko D, Szabó E, Czibula Á, Fajka-Boja R, Kriston-Pál É, Monostori É, Kovács L.

Immunobiology. 2015 Apr;220(4):483-9. doi: 10.1016/j.imbio.2014.10.023. Epub 2014 Oct 30.

PMID:
25468561
9.

Sleep-disordered breathing in neurologic conditions.

Deak MC, Kirsch DB.

Clin Chest Med. 2014 Sep;35(3):547-56. doi: 10.1016/j.ccm.2014.06.009. Epub 2014 Jul 25. Review.

PMID:
25156770
10.

The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver.

Patel K, Foretz M, Marion A, Campbell DG, Gourlay R, Boudaba N, Tournier E, Titchenell P, Peggie M, Deak M, Wan M, Kaestner KH, Göransson O, Viollet B, Gray NS, Birnbaum MJ, Sutherland C, Sakamoto K.

Nat Commun. 2014 Aug 4;5:4535. doi: 10.1038/ncomms5535.

11.

The impact of the P2X7 receptor antagonist A-804598 on neuroimmune and behavioral consequences of stress.

Catanzaro JM, Hueston CM, Deak MM, Deak T.

Behav Pharmacol. 2014 Sep;25(5-6):582-98. doi: 10.1097/FBP.0000000000000072.

PMID:
25083574
12.

Mechanism of action of compound-13: an α1-selective small molecule activator of AMPK.

Hunter RW, Foretz M, Bultot L, Fullerton MD, Deak M, Ross FA, Hawley SA, Shpiro N, Viollet B, Barron D, Kemp BE, Steinberg GR, Hardie DG, Sakamoto K.

Chem Biol. 2014 Jul 17;21(7):866-79. doi: 10.1016/j.chembiol.2014.05.014.

13.

Structural basis for the recruitment of glycogen synthase by glycogenin.

Zeqiraj E, Tang X, Hunter RW, García-Rocha M, Judd A, Deak M, von Wilamowitz-Moellendorff A, Kurinov I, Guinovart JJ, Tyers M, Sakamoto K, Sicheri F.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):E2831-40. doi: 10.1073/pnas.1402926111. Epub 2014 Jun 30.

14.

Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1βMYPT1 phosphatase complex and the SCFβTrCP E3 ubiquitin ligase.

Banerjee S, Zagórska A, Deak M, Campbell DG, Prescott AR, Alessi DR.

Biochem J. 2014 Jul 15;461(2):233-45. doi: 10.1042/BJ20140408.

15.

Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome.

Deák M, Bocskai M, Burcsár S, Dányi O, Fekete Z, Kovács L.

Lupus. 2014 Aug;23(9):913-8. doi: 10.1177/0961203314531839. Epub 2014 Apr 11.

PMID:
24729279
16.

Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662.

Ducommun S, Ford RJ, Bultot L, Deak M, Bertrand L, Kemp BE, Steinberg GR, Sakamoto K.

Am J Physiol Endocrinol Metab. 2014 Mar;306(6):E688-96. doi: 10.1152/ajpendo.00672.2013. Epub 2014 Jan 14.

17.

The WNK-regulated SPAK/OSR1 kinases directly phosphorylate and inhibit the K+-Cl- co-transporters.

de Los Heros P, Alessi DR, Gourlay R, Campbell DG, Deak M, Macartney TJ, Kahle KT, Zhang J.

Biochem J. 2014 Mar 15;458(3):559-73. doi: 10.1042/BJ20131478.

18.

GM1 controlled lateral segregation of tyrosine kinase Lck predispose T-cells to cell-derived galectin-1-induced apoptosis.

Novák J, Kriston-Pál É, Czibula Á, Deák M, Kovács L, Monostori É, Fajka-Boja R.

Mol Immunol. 2014 Feb;57(2):302-9. doi: 10.1016/j.molimm.2013.10.010. Epub 2013 Nov 12.

PMID:
24231767
19.

The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.

Szalay B, Vásárhelyi B, Cseh A, Tulassay T, Deák M, Kovács L, Balog A.

Clin Rheumatol. 2014 Feb;33(2):175-85. doi: 10.1007/s10067-013-2352-x. Epub 2013 Aug 11.

PMID:
23934385
20.

Neuroimmune interactions in Sjögren's syndrome: relationship of exocrine gland dysfunction with autoantibodies to muscarinic acetylcholine receptor-3 and mental health status parameters.

Deák M, Szvetnik A, Balog A, Sohár N, Varga R, Pokorny G, Tóth G, Kiss M, Kovács L.

Neuroimmunomodulation. 2013;20(2):79-86. doi: 10.1159/000345177. Epub 2012 Dec 12.

PMID:
23235351
21.

Insomnia.

Deak MC, Winkelman JW.

Neurol Clin. 2012 Nov;30(4):1045-66. doi: 10.1016/j.ncl.2012.08.012. Review.

PMID:
23099129
22.

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H, Wilson-Delfosse AL, Chen SG.

Hum Mol Genet. 2013 Jan 15;22(2):328-44. doi: 10.1093/hmg/dds431. Epub 2012 Oct 12.

23.

Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.

Toldi G, Szalay B, Bekő G, Bocskai M, Deák M, Kovács L, Vásárhelyi B, Balog A.

Biomarkers. 2012 Dec;17(8):758-63. doi: 10.3109/1354750X.2012.728623. Epub 2012 Oct 4.

PMID:
23033975
24.

PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65.

Kondapalli C, Kazlauskaite A, Zhang N, Woodroof HI, Campbell DG, Gourlay R, Burchell L, Walden H, Macartney TJ, Deak M, Knebel A, Alessi DR, Muqit MM.

Open Biol. 2012 May;2(5):120080. doi: 10.1098/rsob.120080.

25.

The Dac-tag, an affinity tag based on penicillin-binding protein 5.

Lee DW, Peggie M, Deak M, Toth R, Gage ZO, Wood N, Schilde C, Kurz T, Knebel A.

Anal Biochem. 2012 Sep 1;428(1):64-72. doi: 10.1016/j.ab.2012.06.007. Epub 2012 Jun 15.

26.

Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations.

Woodroof HI, Pogson JH, Begley M, Cantley LC, Deak M, Campbell DG, van Aalten DM, Whitworth AJ, Alessi DR, Muqit MM.

Open Biol. 2011 Nov;1(3):110012. doi: 10.1098/rsob.110012.

27.

SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation.

Thastrup JO, Rafiqi FH, Vitari AC, Pozo-Guisado E, Deak M, Mehellou Y, Alessi DR.

Biochem J. 2012 Jan 1;441(1):325-37. doi: 10.1042/BJ20111879.

28.

Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy.

Szalay B, Mészáros G, Cseh Á, Ács L, Deák M, Kovács L, Vásárhelyi B, Balog A.

Clin Dev Immunol. 2012;2012:808724. doi: 10.1155/2012/808724. Epub 2011 Sep 28.

29.

The role of sleep in forgetting in temporal lobe epilepsy: a pilot study.

Deak MC, Stickgold R, Pietras AC, Nelson AP, Bubrick EJ.

Epilepsy Behav. 2011 Aug;21(4):462-6. doi: 10.1016/j.yebeh.2011.04.061. Epub 2011 Jun 28.

30.

TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development.

Bouskila M, Esoof N, Gay L, Fang EH, Deak M, Begley MJ, Cantley LC, Prescott A, Storey KG, Alessi DR.

Biochem J. 2011 Jul 1;437(1):157-67. doi: 10.1042/BJ20110276.

31.

MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases.

Filippi BM, de los Heros P, Mehellou Y, Navratilova I, Gourlay R, Deak M, Plater L, Toth R, Zeqiraj E, Alessi DR.

EMBO J. 2011 May 4;30(9):1730-41. doi: 10.1038/emboj.2011.78. Epub 2011 Mar 18.

32.

Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and -independent pathways.

Richardson C, Sakamoto K, de los Heros P, Deak M, Campbell DG, Prescott AR, Alessi DR.

J Cell Sci. 2011 Mar 1;124(Pt 5):789-800. doi: 10.1242/jcs.077230.

33.

Temporal differences in the dependency on phosphoinositide-dependent kinase 1 distinguish the development of invariant Valpha14 NKT cells and conventional T cells.

Finlay DK, Kelly AP, Clarke R, Sinclair LV, Deak M, Alessi DR, Cantrell DA.

J Immunol. 2010 Nov 15;185(10):5973-82. doi: 10.4049/jimmunol.1000827. Epub 2010 Oct 13.

34.

Phosphorylation of STIM1 at ERK1/2 target sites modulates store-operated calcium entry.

Pozo-Guisado E, Campbell DG, Deak M, Alvarez-Barrientos A, Morrice NA, Alvarez IS, Alessi DR, Martín-Romero FJ.

J Cell Sci. 2010 Sep 15;123(Pt 18):3084-93. doi: 10.1242/jcs.067215. Epub 2010 Aug 24.

35.

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.

Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ.

Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784.

36.

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.

Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR.

Biochem J. 2010 Sep 15;430(3):393-404. doi: 10.1042/BJ20100483.

37.

Sleep and cognition.

Deak MC, Stickgold R.

Wiley Interdiscip Rev Cogn Sci. 2010 Jul;1(4):491-500. doi: 10.1002/wcs.52. Epub 2010 Feb 1.

38.

New roles for the LKB1-NUAK pathway in controlling myosin phosphatase complexes and cell adhesion.

Zagórska A, Deak M, Campbell DG, Banerjee S, Hirano M, Aizawa S, Prescott AR, Alessi DR.

Sci Signal. 2010 Mar 30;3(115):ra25. doi: 10.1126/scisignal.2000616.

39.

Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.

Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM.

Science. 2009 Dec 18;326(5960):1707-11. doi: 10.1126/science.1178377. Epub 2009 Nov 5.

40.

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.

Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR.

Biochem J. 2009 Oct 23;424(1):47-60. doi: 10.1042/BJ20091035.

41.

ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor.

Zeqiraj E, Filippi BM, Goldie S, Navratilova I, Boudeau J, Deak M, Alessi DR, van Aalten DM.

PLoS Biol. 2009 Jun 9;7(6):e1000126. doi: 10.1371/journal.pbio.1000126. Epub 2009 Jun 9.

42.

Structure of the OSR1 kinase, a hypertension drug target.

Villa F, Deak M, Alessi DR, van Aalten DM.

Proteins. 2008 Dec;73(4):1082-7. doi: 10.1002/prot.22238. No abstract available.

PMID:
18831043
43.

Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains.

Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, Alessi DR.

Biochem J. 2008 Apr 15;411(2):249-60. doi: 10.1042/BJ20080067.

PMID:
18254724
44.

Structural insights into the recognition of substrates and activators by the OSR1 kinase.

Villa F, Goebel J, Rafiqi FH, Deak M, Thastrup J, Alessi DR, van Aalten DM.

EMBO Rep. 2007 Sep;8(9):839-45. Epub 2007 Aug 17.

45.

Identification of Protor as a novel Rictor-binding component of mTOR complex-2.

Pearce LR, Huang X, Boudeau J, Pawłowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR.

Biochem J. 2007 Aug 1;405(3):513-22.

46.

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.

Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR.

Biochem J. 2007 Jul 15;405(2):307-17.

47.

The hyper-fluorescent trichome phenotype of the brt1 mutant of Arabidopsis is the result of a defect in a sinapic acid: UDPG glucosyltransferase.

Sinlapadech T, Stout J, Ruegger MO, Deak M, Chapple C.

Plant J. 2007 Feb;49(4):655-68. Epub 2007 Jan 1.

48.

Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress.

Zagórska A, Pozo-Guisado E, Boudeau J, Vitari AC, Rafiqi FH, Thastrup J, Deak M, Campbell DG, Morrice NA, Prescott AR, Alessi DR.

J Cell Biol. 2007 Jan 1;176(1):89-100. Epub 2006 Dec 26.

49.

Identification of novel phosphorylation sites in MSK1 by precursor ion scanning MS.

McCoy CE, macdonald A, Morrice NA, Campbell DG, Deak M, Toth R, McIlrath J, Arthur JS.

Biochem J. 2007 Mar 15;402(3):491-501.

50.

Regulation of the polarity kinases PAR-1/MARK by 14-3-3 interaction and phosphorylation.

Göransson O, Deak M, Wullschleger S, Morrice NA, Prescott AR, Alessi DR.

J Cell Sci. 2006 Oct 1;119(Pt 19):4059-70. Epub 2006 Sep 12.

Supplemental Content

Support Center